Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement ...

Remember CETP? It was a hot topic in cholesterol-lowering drug development a few years ago, but when Merck & Co finally pulled the plug on anacetrapib five years ago on lacklustre phase 3 data ...